| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Felix Kratz, Bakheet Elsade. Clinical impact of serum proteins on drug delivery. Journal of controlled release : official journal of the Controlled Release Society. vol 161. issue 2. 2012-10-25. PMID:22155554. |
for treating diabetes, levemir and victoza that are myristic acid derivatives of human insulin or glucagon-like peptide 1 (glp-1) act as long-acting peptides by binding to the fatty acid binding sites on circulating albumin to control glucose levels. |
2012-10-25 |
2023-08-12 |
human |
| Lin Wu, Anna Olverling, Liselotte Fransson, Henrik Ortsäter, Camilla Kappe, Xin Gao, Ake Sjöhol. Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats. Regulatory peptides. vol 177. issue 1-3. 2012-10-24. PMID:22587909. |
since native glp-1 exerts vascular effects, we investigated changes in pancreatic islet blood flow using a non-radioactive microsphere technique, as well as insulin concentration and glucose tolerance after 17 day treatment with liraglutide in 6-week-old goto-kakizaki (gk) rats. |
2012-10-24 |
2023-08-12 |
rat |
| Manash P Baruah, Sanjay Kalr. The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus. Recent patents on endocrine, metabolic & immune drug discovery. vol 6. issue 2. 2012-10-16. PMID:22435393. |
the novel use of glp-1 analogue and insulin combination in type 2 diabetes mellitus. |
2012-10-16 |
2023-08-12 |
Not clear |
| Manash P Baruah, Sanjay Kalr. The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus. Recent patents on endocrine, metabolic & immune drug discovery. vol 6. issue 2. 2012-10-16. PMID:22435393. |
attempts have been made to combine glp-1 analogues with basal insulin for management of t2dm. |
2012-10-16 |
2023-08-12 |
Not clear |
| Manash P Baruah, Sanjay Kalr. The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus. Recent patents on endocrine, metabolic & immune drug discovery. vol 6. issue 2. 2012-10-16. PMID:22435393. |
glp-1 analogue and insulin as fdc or by co-administration, is a rational method of controlling fasting and postprandial glucose effectively. |
2012-10-16 |
2023-08-12 |
Not clear |
| Manash P Baruah, Sanjay Kalr. The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus. Recent patents on endocrine, metabolic & immune drug discovery. vol 6. issue 2. 2012-10-16. PMID:22435393. |
this review summarizes the current status of glp-1 and insulin combination in the management of t2dm and highlights the new frontiers in research involving glp-1. |
2012-10-16 |
2023-08-12 |
Not clear |
| Manash P Baruah, Sanjay Kalr. The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus. Recent patents on endocrine, metabolic & immune drug discovery. vol 6. issue 2. 2012-10-16. PMID:22435393. |
patents on combination of glp-1 and insulin which were granted earlier, and the ones which have been applied for, are also discussed. |
2012-10-16 |
2023-08-12 |
Not clear |
| Hyoseok Kan. Current therapeutic agents and anesthetic considerations for diabetes mellitus. Korean journal of anesthesiology. vol 63. issue 3. 2012-10-15. PMID:23060974. |
in addition to the conventional therapy for dm, glucagon-like peptide-1 (glp-1) mimetics, dipeptidyl peptidase-4 (dpp-4) inhibitors, thiazolidinediones (tzds), and insulin analogues are currently available effective hypoglycemic agents for the management of the patients with dm in the perioperative period and also consider the adverse effects of newly introduced agents that need more clinical observations. |
2012-10-15 |
2023-08-12 |
Not clear |
| Boldbaatar Damdindorj, Katsuya Dezaki, Tomoyuki Kurashina, Hideyuki Sone, Rauza Rita, Masafumi Kakei, Toshihiko Yad. Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet β-cells. FEBS letters. vol 586. issue 16. 2012-10-12. PMID:22750144. |
exogenous and endogenous ghrelin counteracts glp-1 action to stimulate camp signaling and insulin secretion in islet β-cells. |
2012-10-12 |
2023-08-12 |
rat |
| Boldbaatar Damdindorj, Katsuya Dezaki, Tomoyuki Kurashina, Hideyuki Sone, Rauza Rita, Masafumi Kakei, Toshihiko Yad. Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet β-cells. FEBS letters. vol 586. issue 16. 2012-10-12. PMID:22750144. |
glp-1 potentiated glucose-induced insulin release and camp production in isolated islets and [ca(2+)](i) increases in single β-cells, and these potentiations were attenuated by ghrelin. |
2012-10-12 |
2023-08-12 |
rat |
| Boldbaatar Damdindorj, Katsuya Dezaki, Tomoyuki Kurashina, Hideyuki Sone, Rauza Rita, Masafumi Kakei, Toshihiko Yad. Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet β-cells. FEBS letters. vol 586. issue 16. 2012-10-12. PMID:22750144. |
these results indicate that both exogenous and endogenous islet-derived ghrelin counteracts glucose-dependent glp-1 action to increase camp production, [ca(2+)](i) and insulin release in islet β-cells, positioning ghrelin as a modulator of insulinotropic glp-1. |
2012-10-12 |
2023-08-12 |
rat |
| Jill L Buss, Amer Rajab, Elizabeth D Essig, Valerie K Bergdall, Jie Wang, Kwame Ose. Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant only. Journal of transplantation. vol 2012. 2012-10-12. PMID:23056916. |
the glp-1 receptor agonist, exenatide, has previously been shown to improve insulin secretion, protect beta cells from apoptosis, and promote beta cell regeneration. |
2012-10-12 |
2023-08-12 |
monkey |
| Denise Wootten, Emilia E Savage, Celine Valant, Lauren T May, Kyle W Sloop, James Ficorilli, Aaron D Showalter, Francis S Willard, Arthur Christopoulos, Patrick M Sexto. Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Molecular pharmacology. vol 82. issue 2. 2012-10-09. PMID:22576254. |
modulation of glp-1(9-36)nh(2) was also demonstrated in ex vivo and in vivo assays of insulin secretion. |
2012-10-09 |
2023-08-12 |
Not clear |
| Peijian Wang, Zhencheng Yan, Jian Zhong, Jing Chen, Yinxing Ni, Li Li, Liqun Ma, Zhigang Zhao, Daoyan Liu, Zhiming Zh. Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis. Diabetes. vol 61. issue 8. 2012-10-08. PMID:22664955. |
acute capsaicin administration by gastric gavage increased glp-1 and insulin secretion in vivo in wt but not in trpv1(-/-) mice. |
2012-10-08 |
2023-08-12 |
mouse |
| Peijian Wang, Zhencheng Yan, Jian Zhong, Jing Chen, Yinxing Ni, Li Li, Liqun Ma, Zhigang Zhao, Daoyan Liu, Zhiming Zh. Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis. Diabetes. vol 61. issue 8. 2012-10-08. PMID:22664955. |
furthermore, chronic dietary capsaicin not only improved glucose tolerance and increased insulin levels but also lowered daily blood glucose profiles and increased plasma glp-1 levels in wt mice. |
2012-10-08 |
2023-08-12 |
mouse |
| Harold W de Val. DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. The review of diabetic studies : RDS. vol 4. issue 3. 2012-10-02. PMID:18084670. |
oral inhibitors of dpp-4 increase glp-1 levels and this leads to lower glucose levels caused by increased insulin secretion and decreased glucagon levels. |
2012-10-02 |
2023-08-12 |
Not clear |
| Baptist Gallwit. Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. The review of diabetic studies : RDS. vol 6. issue 4. 2012-10-02. PMID:20043037. |
furthermore, glp-1 receptor agonists induce glucose-dependent insulin secretion, beta-cell protection, and other extraglycemic benefits such as weight loss and improvement in markers of cardiovascular risk. |
2012-10-02 |
2023-08-12 |
human |
| Kiwon Ban, Sonya Hui, Daniel J Drucker, Mansoor Husai. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. Journal of the American Society of Hypertension : JASH. vol 3. issue 4. 2012-10-02. PMID:20409967. |
the glp-1 receptor agonists reduce blood glucose levels by stimulating insulin and inhibiting glucagon secretion and gastric emptying. |
2012-10-02 |
2023-08-12 |
mouse |
| Kiwon Ban, Sonya Hui, Daniel J Drucker, Mansoor Husai. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. Journal of the American Society of Hypertension : JASH. vol 3. issue 4. 2012-10-02. PMID:20409967. |
dipeptidyl peptidase-4 (dpp-4) inhibitors prolong the half-life of endogenous glp-1 by inhibiting its proteolytic degradation to the metabolite glp-1(9-36), thereby increasing insulin and reducing glucagon secretion. |
2012-10-02 |
2023-08-12 |
mouse |
| K A Gronau, P L Brubake. Mechanism of action of glucagon-like peptide-1(7-36NH2) in isolated rat pancreatic islets and abrogation of its effects in long-term incubations. Endocrine. vol 3. issue 11. 2012-10-02. PMID:21153123. |
glucagon-like peptide-1(7-37/36nh2) (glp-1) potently stimulates acute glucose-dependent insulin secretionin vitro andin vivo. |
2012-10-02 |
2023-08-12 |
rat |